An exploratory study of circulating cytokines and chemokines in patients with muscle disorders proposes CD40L and CCL5 represent general disease markers while CXCL10 differentiates between patients with an autoimmune myositis. Issue 1 (March 2022)

• Record Type: Journal Article
• Authors: De Paepe, Boel; Bracke, Ken R.; De Bleecker, Jan L.
• Is Part Of: Cytokine. Volume 4:Issue 1(2022)
• Publication Date: 2022-03
• Subjects: Autoimmune myositis -- CCL5 -- CD40L -- Chemokines -- CXCL10 immune-mediated necrotizing myopathy -- Sporadic inclusion body myositis
• DOI: 10.1016/j.cytox.2022.100063
• Languages: English
• ISSNs: 2590-1532

Abstract

Graphical abstract: Highlights: Circulating cytokines/chemokines represent patient-friendly diagnostic markers. Serum levels of CD40L and CCL5 are increased in different muscle diseases. CXCL10 levels are significantly elevated only in the autoimmune myositis patients. CXCL10 levels are significantly higher in sporadic inclusion body myositis. Abstract: Discriminating an autoimmune myositis from other disorders and subtyping of patient groups within this heterogeneous group of conditions remain diagnostic challenges. In our study we explored the potential of cytokine and chemokine typing in patient sera as an addition to the expanding set of blood-accessible diagnostic biomarkers available today. We selected sets of ten patients within well-characterized disease groups representing healthy controls, and patients with hereditary muscular dystrophies, immune-mediated necrotizing myopathy (IMNM) and sporadic inclusion body myositis (IBM). Prescreening using proteome arrays singled out three biomarker candidates, being the cytokine CD40L, and chemokines CXCL10 and CCL5. Enzyme-linked immunosorbent assays showed all three markers to be elevated in muscle disease irrespective of patient subgroup. CXCL10 levels on the other hand were higher in autoimmune myositis only, and levels were significantly higher in IBM compared to IMNM. The strong CXCL10 expression observed in the auto-aggressive inflammatory cells within IBM muscle tissues possibly represents a major source of circulating CXCL10. We conclude that CXCL10 levels could represent a convenient marker for autoimmune myositis indicative of patient subgroups.